Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma.

Vogl DT, Wang T, Pérez WS, Stadtmauer EA, Heitjan DF, Lazarus HM, Kyle RA, Kamble R, Weisdorf D, Roy V, Gibson J, Ballen K, Holmberg L, Bashey A, McCarthy PL, Freytes C, Maharaj D, Maiolino A, Vesole D, Hari P.

Biol Blood Marrow Transplant. 2011 Dec;17(12):1765-74. doi: 10.1016/j.bbmt.2011.05.005. Epub 2011 May 11.

2.

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial.

Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F, Sotto JJ, Guilhot F, Marit G, Doyen C, Jaubert J, Fuzibet JG, François S, Benboubker L, Monconduit M, Voillat L, Macro M, Berthou C, Dorvaux V, Pignon B, Rio B, Matthes T, Casassus P, Caillot D, Najman N, Grosbois B, Bataille R, Harousseau JL; Intergroupe Francophone du Myélome.

Blood. 2002 Feb 1;99(3):731-5.

3.

Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Spanish Registry for Transplant in MM (Grupo Español de Trasplante Hematopoyético-GETH) and PETHEMA.

Alegre A, Díaz-Mediavilla J, San-Miguel J, Martínez R, García Laraña J, Sureda A, Lahuerta JJ, Morales D, Bladé J, Caballero D, De la Rubia J, Escudero A, Díez-Martín JL, Hernández-Navarro F, Rifón J, Odriozola J, Brunet S, De la Serna J, Besalduch J, Vidal MJ, Solano C, Leon A, Sánchez JJ, Martínez-Chamorro C, Fernández-Rañada JM.

Bone Marrow Transplant. 1998 Jan;21(2):133-40.

4.

A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma.

Bashir Q, Khan H, Thall PF, Liu P, Shah N, Kebriaei P, Parmar S, Oran B, Ciurea S, Nieto Y, Jones R, Hosing CM, Popat UR, Dinh YT, Rondon G, Orlowski RZ, Shah JJ, De Lima M, Shpall E, Champlin R, Giralt S, Qazilbash MH.

Biol Blood Marrow Transplant. 2013 Oct;19(10):1453-8. doi: 10.1016/j.bbmt.2013.07.008. Epub 2013 Jul 17.

5.

Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning--evidence for a superior outcome using melphalan combined with total body irradiation.

Hunter HM, Peggs K, Powles R, Rahemtulla A, Mahendra P, Cavenagh J, Littlewood T, Potter M, Hunter A, Pagliuca A, Williams CD, Cook G, Towlson K, Marks David I, Russell NH; Clinical Trials Committee of the British Society of Blood and Marrow Transplantation (BSBMT).

Br J Haematol. 2005 Feb;128(4):496-502.

PMID:
15686458
6.

A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma.

Mark TM, Reid W, Niesvizky R, Gergis U, Pearse R, Mayer S, Greenberg J, Coleman M, Van Besien K, Shore T.

Biol Blood Marrow Transplant. 2013 May;19(5):831-7. doi: 10.1016/j.bbmt.2013.02.013. Epub 2013 Feb 20.

7.

Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes.

Christoforidou AV, Saliba RM, Williams P, Qazilbash M, Roden L, Aleman A, Weber D, Mendoza F, Podoloff D, Wendt R 3rd, Breitz H, Alexanian R, Champlin R, Giralt S.

Biol Blood Marrow Transplant. 2007 May;13(5):543-9. Epub 2007 Feb 26.

8.

Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma.

Saad A, Mahindra A, Zhang MJ, Zhong X, Costa LJ, Dispenzieri A, Drobyski WR, Freytes CO, Gale RP, Gasparetto CJ, Holmberg LA, Kamble RT, Krishnan AY, Kyle RA, Marks D, Nishihori T, Pasquini MC, Ramanathan M, Lonial S, Savani BN, Saber W, Sharma M, Sorror ML, Wirk BM, Hari PN.

Biol Blood Marrow Transplant. 2014 Mar;20(3):402-408.e1. doi: 10.1016/j.bbmt.2013.12.557. Epub 2013 Dec 14.

9.

BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.

Veeraputhiran M, Jain T, Deol A, Ayash L, Kim S, Dyson G, Bhutani D, Lum LG, Ratanatharathorn V, Uberti JP, Abidi MH.

Clin Lymphoma Myeloma Leuk. 2015 Sep;15(9):531-5. doi: 10.1016/j.clml.2015.05.008. Epub 2015 Jun 6.

PMID:
26166312
10.

Comparison of 1-day vs 2-day dosing of high-dose melphalan followed by autologous hematopoietic cell transplantation in patients with multiple myeloma.

Parmar SR, Bookout R, Shapiro JF, Tombleson R, Perkins J, Kim J, Yue B, Tomblyn M, Alsina M, Nishihori T.

Bone Marrow Transplant. 2014 Jun;49(6):761-6. doi: 10.1038/bmt.2014.56. Epub 2014 Mar 24.

PMID:
24662419
11.

Late relapses following reduced intensity allogeneic transplantation in patients with multiple myeloma: a long-term follow-up study.

Sahebi F, Shen Y, Thomas SH, Rincon A, Murata-Collins J, Palmer J, Krishnan AY, Karanes C, Htut M, Somlo G, Forman SJ.

Br J Haematol. 2013 Jan;160(2):199-206. doi: 10.1111/bjh.12123. Epub 2012 Nov 15.

12.

Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients.

El Fakih R, Fox P, Popat U, Nieto Y, Shah N, Parmar S, Oran B, Ciurea S, Kebriaei P, Hosing C, Ahmed S, Shah J, Orlowski R, Champlin R, Qazilbash M, Bashir Q.

Clin Lymphoma Myeloma Leuk. 2015 Aug;15(8):472-6. doi: 10.1016/j.clml.2015.03.003. Epub 2015 Mar 27.

13.
14.

High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study.

Musso M, Messina G, Marcacci G, Crescimanno A, Console G, Donnarumma D, Scalone R, Pinto A, Martino M.

Biol Blood Marrow Transplant. 2015 Nov;21(11):1932-8. doi: 10.1016/j.bbmt.2015.06.011. Epub 2015 Jun 19.

15.

Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up.

Björkstrand B, Iacobelli S, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Musto P, Beksac M, Bosi A, Milone G, Corradini P, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Gahrton G.

J Clin Oncol. 2011 Aug 1;29(22):3016-22. doi: 10.1200/JCO.2010.32.7312. Epub 2011 Jul 5. Erratum in: J Clin Oncol. 2011 Sep 20;29(27):3721.

PMID:
21730266
16.

Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma.

Lahuerta JJ, Martinez-Lopez J, Grande C, Bladé J, de la Serna J, Alegre A, García-Laraña J, Caballero D, Sureda A, de la Rubia J, Alvarez AM, Marín J, Escudero A, Conde E, Perez-Equiza K, García Ruiz JC, Moraleda JM, León A, Bargay J, Cabrera R, Hernandez-García MT, Diaz-Mediavilla J, Miguel JS.

Br J Haematol. 2000 Apr;109(1):138-47.

PMID:
10848793
17.

Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting.

Rotta M, Storer BE, Sahebi F, Shizuru JA, Bruno B, Lange T, Agura ED, McSweeney PA, Pulsipher MA, Hari P, Maziarz RT, Chauncey TR, Appelbaum FR, Sorror ML, Bensinger W, Sandmaier BM, Storb RF, Maloney DG.

Blood. 2009 Apr 2;113(14):3383-91. doi: 10.1182/blood-2008-07-170746. Epub 2008 Nov 17.

18.

Optimal dosing of melphalan as high-dose therapy before autologous hematopoietic stem cell transplantation in myeloma patients with solitary kidney: a case series.

Nooka AK, Harvey RD, Langston A, Collins H, Lonial S, Kaufman JL.

Clin Lymphoma Myeloma Leuk. 2014 Apr;14(2):e59-63. doi: 10.1016/j.clml.2013.11.007. Epub 2013 Nov 15. No abstract available.

PMID:
24378319
19.

Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.

Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, McCoy J, Moore DF Jr, Dakhil SR, Lanier KS, Chapman RA, Cromer JN, Salmon SE, Durie B, Crowley JC.

J Clin Oncol. 2006 Feb 20;24(6):929-36. Epub 2006 Jan 23. Erratum in: J Clin Oncol. 2006 Jun 10;24(17):2687. Moore, Dennis F Jr [added].

PMID:
16432076
20.

Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma.

William BM, Loberiza FR Jr, Whalen V, Bierman PJ, Bociek RG, Vose JM, Armitage JO.

Clin Lymphoma Myeloma Leuk. 2013 Aug;13(4):417-23. doi: 10.1016/j.clml.2013.03.009. Epub 2013 Jun 15.

PMID:
23773453

Supplemental Content

Support Center